P139 Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD) - preclinical and early clinical development.

Beatriz F Lindstrom, Jon L Ruckle, Stewart A Turner, Kathe Stauber, Stuart M Brierley, Brett A English, Bruce Yacyshyn

Research output: Contribution to journalArticlepeer-review

Abstract

Supplementary
Original languageEnglish
Pages (from-to)S64
JournalInflammatory bowel diseases
Volume25
Issue numberSupplement_1
DOIs
Publication statusPublished or Issued - 7 Feb 2019

Cite this